Lobular neoplasia of the breast

Breast Journal

Volumn 16, Issue 5, 2010, Pages 519-528

  Venkitaraman, Ramachandran ^a  

^a IPSWICH HOSPITAL NHS TRUST   (United Kingdom)

Author keywords

Atypical lobular hyperplasia; Breast; Lobular carcinoma in situ; Lobular neoplasia

Indexed keywords

AROMATASE INHIBITOR; RALOXIFENE; TAMOXIFEN;

ARTICLE; BREAST BIOPSY; BREAST SURGERY; BREAST TUMOR; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER SCREENING; CARCINOMA IN SITU; DIAGNOSTIC IMAGING; EXCISION; HETEROZYGOSITY LOSS; HIGH RISK PATIENT; HUMAN; HYPERPLASIA; LOBULAR NEOPLASIA; MAMMOGRAPHY; MASTECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PREVALENCE; PROSPECTIVE STUDY; RISK REDUCTION; TREATMENT INDICATION; TUMOR RECURRENCE;

BREAST NEOPLASMS; CARCINOMA, LOBULAR; FEMALE; HUMANS;

EID: 77956835395     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/j.1524-4741.2010.00971.x     Document Type: Article

References (92)

1. Anderson BO, Calhoun KE, Rosen EL. Evolving concepts in the management of lobular neoplasia. J Natl Compr Canc Netw 2006;4:511-522
2. Bibeau F, Borrelly C, Chateau MC, et al. (Recent data on lobular neoplasia of the breast: The pathologist's opinion). Bull Cancer 2005;92:453-458
3. Frykberg ER. Lobular carcinoma in situ of the breast. Breast J 1999;5:296-303.
4. Afonso N, Bouwman D. Lobular carcinoma in situ. Eur J Cancer Prev 2008;17:312-316
5. Goldstein NS, Kestin LL, Vicini FA. Clinicopathologic implications of E-cadherin reactivity in patients with lobular carcinoma in situ of the breast. Cancer 2001;92:738-747
6. Fentiman IS. 8. The dilemma of in situ carcinoma of the breast. Int J Clin Pract 2001;55:680-683
7. Chuba PJ, Hamre MR, Yap J, et al. Bilateral risk for subsequent breast cancer after lobular carcinoma-in-situ: Analysis of surveillance, epidemiology, and end results data. J Clin Oncol 2005;23:5534-5541
8. Page DL, Kidd TE Jr, Dupont WD, Simpson JF, Rogers LW. Lobular neoplasia of the breast. higher risk for subsequent invasive cancer predicted by more extensive disease. Hum Pathol 1991;22:1232-1239
9. Haagensen CD, Lane N, Lattes R, Bodian C. Lobular neoplasia (so-called lobular carcinoma in situ) of the breast. Cancer 1978;42:737-769
10. Li CI, Anderson BO, Daling JR, Moe RE. Changing incidence of lobular carcinoma in situ of the breast. Breast Cancer Res Treat 2002;75:259-268
11. Li CI, Daling JR, Malone KE. Age-specific incidence rates of in situ breast carcinomas by histologic type, 1980 to 2001. Cancer Epidemiol Biomarkers Prev 2005;14:1008-1011
12. Barchielli A, Federico M, De Lisi V, et al. In situ breast cancer: Incidence trend and organised screening programmes in Italy. Eur J Cancer 2005;41:1045-1050
13. Akashi-Tanaka S, Fukutomi T, Nanasawa T, Matsuo K, Hasegawa T, Tsuda H. Treatment of noninvasive carcinoma. fifteen-year results at the National Cancer Center Hospital in Tokyo. Breast Cancer 2000;7:341-344
14. Beute BJ, Kalisher L, Hutter RV. Lobular carcinoma in situ of the breast: Clinical, pathologic, and mammographic features. AJR Am J Roentgenol 1991;157:257-265
15. Claus EB, Stowe M, Carter D. Family history of breast and ovarian cancer and the risk of breast carcinoma in situ. Breast Cancer Res Treat 2003;78:7-15. (Pubitemid 36223012)
16. Reeves GK, Beral V, Green J, Gathani T, Bull D. Hormonal therapy for menopause and breast-cancer risk by histological type: A cohort study and meta-analysis. Lancet Oncol 2006;7:910-918
17. Mastracci TL, Boulos FI, Andrulis IL, Lam WL. Genomics and premalignant breast lesions: Clues to the development and progression of lobular breast cancer. Breast Cancer Res 2007;9:215.
18. Hanby AM, Hughes TA. In situ and invasive lobular neoplasia of the breast. Histopathology 2008;52:58-66.
19. Ringberg A, Palmer B, Linell F, Rychterova V, Ljungberg O. Bilateral and multifocal breast carcinoma. A clinical and autopsy study with special emphasis on carcinoma in situ. Eur J Surg Oncol 1991;17:20-29
20. Bratthauer GL, Tavassoli FA. Lobular intraepithelial neoplasia: Previously unexplored aspects assessed in 775 cases and their clinical implications. Virchows Arch 2002;440:134-138
21. Mohsin SK, O'Connell P, Allred DC, Libby AL. Biomarker profile and genetic abnormalities in lobular carcinoma in situ. Breast Cancer Res Treat 2005;90:249-256
22. Albonico G, Querzoli P, Ferretti S, Rinaldi R, Nenci I. Biological profile of in situ breast cancer investigated by immunohistochemical technique. Cancer Detect Prev 1998;22:313-318
23. Dabbs DJ, Bhargava R, Chivukula M. Lobular versus ductal breast neoplasms: The diagnostic utility of p120 catenin. Am J Surg Pathol 2007;31:427-437
24. Nonni A, Zagouri F, Sergentanis TN, Lazaris AC, Patsouris ES, Zografos GC. Immunohistochemical expression of estrogen receptors alpha and beta in lobular neoplasia. Virchows Arch 2007;451:893-897
25. Da Silva L, Parry S, Reid L, et al. Aberrant expression of E-cadherin in lobular carcinomas of the breast. Am J Surg Pathol 2008;32:773-783
26. Mastracci TL, Tjan S, Bane AL, O'Malley FP, Andrulis IL. E-cadherin alterations in atypical lobular hyperplasia and lobular carcinoma in situ of the breast. Mod Pathol 2005;18:741-751
27. Lu YJ, Osin P, Lakhani SR, Di Palma S, Gusterson BA, Shipley JM. Comparative genomic hybridization analysis of lobular carcinoma in situ and atypical lobular hyperplasia and potential roles for gains and losses of genetic material in breast neoplasia. Cancer Res 1998;58:4721-4727
28. Mastracci TL, Shadeo A, Colby SM, et al. Genomic alterations in lobular neoplasia: A microarray comparative genomic hybridization signature for early neoplastic proliferationin the breast. Genes Chromosomes Cancer 2006;45:1007-1017
29. Morandi L, Marucci G, Foschini MP, et al. Genetic similarities and differences between lobular in situ neoplasia (LN) and invasive lobular carcinoma of the breast. Virchows Arch 2006;449:14-23.
30. Abdel-Fatah TM, Powe DG, Hodi Z, Lee AH, Reis-Filho JS, Ellis IO. High frequency of coexistence of columnar cell lesions, lobular neoplasia, and low grade ductal carcinoma in situ with invasive tubular carcinoma and invasive lobular carcinoma. Am J Surg Pathol 2007;31:417-426
31. Vos CB, Cleton-Jansen AM, Berx G, et al. E-cadherin inactivation in lobular carcinoma in situ of the breast: An early event in tumorigenesis. Br J Cancer 1997;76:1131-1133 (Pubitemid 27448007)
32. Etzell JE, Devries S, Chew K, et al. Loss of chromosome 16q in lobular carcinoma in situ. Hum Pathol 2001;32:292-296
33. Aulmann S, Penzel R, Longerich T, Funke B, Schirmacher P, Sinn HP. Clonality of lobular carcinoma in situ (LCIS) and metachronous invasive breast cancer. Breast Cancer Res Treat 2008;107:331-335
34. Aulmann S, Penzel R, Schirmacher P, Sinn HP. Lobular carcinoma in situ (LCIS): Risk factor and precursor of invasive lobular breast cancer. Verh Dtsch Ges Pathol 2007;91:208-213
35. Shelley Hwang E, Nyante SJ, Yi Chen Y, et al. Clonality of lobular carcinoma in situ and synchronous invasive lobular carcinoma. Cancer 2004;100:2562-2572
36. Fadare O, Wang SA, Hileeto D. The expression of cytokeratin 5 /6 in invasive lobular carcinoma of the breast: Evidence of a basal-like subset? Hum Pathol 2008;39:331-336
37. Chivukula M, Haynik DM, Brufsky A, Carter G, Dabbs DJ. Pleomorphic lobular carcinoma in situ (PLCIS) on breast core needle biopsies: Clinical significance and immunoprofile. Am J Surg Pathol 2008;32:1721-1726
38. Simpson PT, Reis-Filho JS, Lambros MB, et al. Molecular profiling pleomorphic lobular carcinomas of the breast: Evidence for a common molecular genetic pathway with classic lobular carcinomas. J Pathol 2008;215:231-244
39. Brandt SM, Young GQ, Hoda SA. The "Rosen Triad": Tubular carcinoma, lobular carcinoma in situ, and columnar cell lesions. Adv Anat Pathol 2008;15:140-146
40. Fisher ER, Costantino J, Fisher B, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17. Five-year observations concerning lobular carcinoma in situ. Cancer 1996;78:1403-1416
41. Krecke KN, Gisvold JJ. Invasive lobular carcinoma of the breast: Mammographic findings and extent of disease at diagnosis in 184 patients. AJR Am J Roentgenol 1993;161:957-960
42. Sonnenfeld MR, Frenna TH, Weidner N, Meyer JE. Lobular carcinoma in situ: Mammographic-pathologic correlation of results of needle-directed biopsy. Radiology 1991;181:363-367
43. Georgian-Smith D, Lawton TJ. Calcifications of lobular carcinoma in situ of the breast: Radiologic-pathologic correlation. AJR Am J Roentgenol 2001;176:1255-1259
44. Cocquyt V, Van Belle S. Lobular carcinoma in situ and invasive lobular cancer of the breast. Curr Opin Obstet Gynecol 2005;17:55-60.
45. Crisi GM, Mandavilli S, Cronin E, Ricci A Jr. Invasive mammary carcinoma after immediate and short-term follow-up for lobular neoplasia on core biopsy. Am J Surg Pathol 2003;27:325-333
46. Margenthaler JA, Duke D, Monsees BS, Barton PT, Clark C, Dietz JR. Correlation between core biopsy and excisional biopsy in breast high-risk lesions. Am J Surg 2006;192:534-537
47. Brem RF, Lechner MC, Jackman RJ, et al. Lobular neoplasia at percutaneous breast biopsy: Variables associated with carcinoma at surgical excision. AJR Am J Roentgenol 2008;190:637-641
48. Bowman K, Munoz A, Mahvi DM, Breslin TM. Lobular neoplasia diagnosed at core biopsy does not mandate surgical excision. J Surg Res 2007;142:275-280
49. Nagi CS, O'Donnell JE, Tismenetsky M, Bleiweiss IJ, Jaffer SM. Lobular neoplasia on core needle biopsy does not require excision. Cancer 2008;112:2152-8.
50. Sohn VY, Arthurs ZM, Kim FS, Brown TA. Lobular neoplasia: Is surgical excision warranted? Am Surg 2008;74:172-177
51. Carson W, Sanchez-Forgach E, Stomper P, Penetrante R, Tsangaris TN, Edge SB. Lobular carcinoma in situ: Observation without surgery as an appropriate therapy. Ann Surg Oncol 1994;1:141-146
52. Berg WA, Mrose HE, Ioffe OB. Atypical lobular hyperplasia or lobular carcinoma in situ at core-needle breast biopsy. Radiology 2001;218:503-509
53. Lavoue V, Graesslin O, Classe JM, Fondrinier E, Angibeau H, Leveque J. Management of lobular neoplasia diagnosed by core needle biopsy: Study of 52 biopsies with follow-up surgical excision. Breast 2007;16:533-539
54. Esserman LE, Lamea L, Tanev S, Poppiti R. Should the extent of lobular neoplasia on core biopsy influence the decision for excision? Breast J 2007;13:55-61.
55. Hwang H, Barke LD, Mendelson EB, Susnik B. Atypical lobular hyperplasia and classic lobular carcinoma in situ in core biopsy specimens: Routine excision is not necessary. Mod Pathol 2008;21:1208-1216
56. Liberman L, Sama M, Susnik B, et al. Lobular carcinoma in situ at percutaneous breast biopsy: Surgical biopsy findings. AJR Am J Roentgenol 1999;173:291-299
57. Shin SJ, Rosen PP. Excisional biopsy should be performed if lobular carcinoma in situ is seen on needle core biopsy. Arch Pathol Lab Med 2002;126:697-701.
58. Andersen JA. Lobular carcinoma in situ of the breast. An approach to rational treatment. Cancer 1977;39:2597-2602
59. Rosen PP, Kosloff C, Lieberman PH, Adair F, Braun DW, Jr. Lobular carcinoma in situ of the breast. Detailed analysis of 99 patients with average follow-up of 24 years. Am J Surg Pathol 1978;2:225-251
60. Fisher ER, Land SR, Fisher B, Mamounas E, Gilarski L, Wolmark N. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: Twelve-year observations concerning lobular carcinoma in situ. Cancer 2004;100:238-244 (Pubitemid 38063630)
61. Hutter RV. The management of patients with lobular carcinoma in situ of the breast. Cancer 1984;53(Suppl 3):798-802.
62. Attene F, Scognamillo F, Trignano E, Meloni GB, Rubino C, Trignano M. (In situ carcinomas of the breast: Clinical features and therapeutic strategies). Ann Ital Chir 2006;77:3-10; discussion 10-12
63. Bradley SJ, Weaver DW, Bouwman DL. Alternatives in the surgical management of in situ breast cancer. A meta-analysis of outcome. Am Surg 1990;56:428-432
64. Cutuli B, de Lafontan B, Quetin P, Mery E. Breast-conserving surgery and radiotherapy: A possible treatment for lobular carcinoma in situ? Eur J Cancer 2005;41:380-385
65. Claus EB, Stowe M, Carter D, Holford T. The risk of a contralateral breast cancer among women diagnosed with ductal and lobular breast carcinoma in situ: Data from the Connecticut Tumor Registry. Breast 2003;12:451-456
66. Adepoju LJ, Symmans WF, Babiera GV, et al. Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy. Cancer 2006;106:42-50.
67. Walt AJ, Simon M, Swanson GM. The continuing dilemma of lobular carcinoma in situ. Arch Surg 1992;127:904-7; discussion 907-909
68. Carolin KA, Tekyi-Mensah S, Pass HA. Lobular carcinoma in situ and invasive cancer: The contralateral breast controversy. Breast J 2002;8:263-268
69. Moran M, Haffty BG. Lobular carcinoma in situ as a component of breast cancer: The long-term outcome in patients treated with breast-conservation therapy. Int J Radiat Oncol Biol Phys 1998;40:353-358
70. Jolly S, Kestin LL, Goldstein NS, Vicini FA. The impact of lobular carcinoma in situ in association with invasive breast cancer on the rate of local recurrence in patients with early-stage breast cancer treated with breast-conserving therapy. Int J Radiat Oncol Biol Phys 2006;66:365-371
71. Mechera R, Viehl CT, Oertli D. Factors predicting in-breast tumor recurrence after breast-conserving surgery. Breast Cancer Res Treat 2009;116:171-177
72. Abner AL, Connolly JL, Recht A, et al. The relation between the presence and extent of lobular carcinoma in situ and the risk of local recurrence for patients with infiltrating carcinoma of the breast treated with conservative surgery and radiation therapy. Cancer 2000;88:1072-1077
73. Ciocca RM, Li T, Freedman GM, Morrow M. Presence of lobular carcinoma in situ does not increase local recurrence in patients treated with breast-conserving therapy. Ann Surg Oncol 2008;15:2263-2271
74. Stolier AJ, Barre G, Bolton JS, Fuhrman GM, Looney S. Breast conservation therapy for invasive lobular carcinoma: The impact of lobular carcinoma in situ in the surgical specimen on local recurrence and axillary node status. Am Surg 2004;70:818-821
75. Ben-David MA, Kleer CG, Paramagul C, Griffith KA, Pierce LJ. Is lobular carcinoma in situ as a component of breast carcinoma a risk factor for local failure after breast-conserving therapy? Results of a matched pair analysis. Cancer 2006;106:28-34.
76. Sasson AR, Fowble B, Hanlon AL, et al. Lobular carcinoma in situ increases the risk of local recurrence in selected patients with stages I and II breast carcinoma treated with conservative surgery and radiation. Cancer 2001;91:1862-1869
77. Port ER, Park A, Borgen PI, Morris E, Montgomery LL. Results of MRI screening for breast cancer in high-risk patients with LCIS and atypical hyperplasia. Ann Surg Oncol 2007;14:1051-1057
78. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-1388
79. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: Current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005;97:1652-1662
80. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Wolmark N. The study of tamoxifen and raloxifene: Preliminary enrollment data from a randomized breast cancer risk reduction trial. Clin Breast Cancer 2002;3:153-159
81. Chun J, El-Tamer M, Joseph KA, Ditkoff BA, Schnabel F. Predictors of breast cancer development in a high-risk population. Am J Surg 2006;192:474-477
82. Fisher ER, Wang J, Bryant J, Fisher B, Mamounas E, Wolmark N. Pathobiology of preoperative chemotherapy: Findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer 2002;95:681-695
83. Arpino G, Allred DC, Mohsin SK, Weiss HL, Conrow D, Elledge RM. Lobular neoplasia on core-needle biopsy-clinical significance. Cancer 2004;01:242-250
84. Elsheikh TM, Silverman JF. Follow-up surgical excision is indicated when breast core needle biopsies show atypical lobular hyperplasia or lobular carcinoma in situ: A correlative study of 33 patients with review of the literature. Am J Surg Pathol 2005;29:534-543
85. Cangiarella J, Guth A, Axelrod D, et al. Is surgical excision necessary for the management of atypical lobular hyperplasia and lobular carcinoma in situ diagnosed on core needle biopsy? A report of 38 cases and review of the literature. Arch Pathol Lab Med 2008;132:979-983
86. Foster MC, Helvie MA, Gregory NE, Rebner M, Nees AV, Paramagul C. Lobular carcinoma in situ or atypical lobular hyperplasia at core-needle biopsy: Is excisional biopsy necessary? Radiology 2004;231:813-819 (Pubitemid 38668103)
87. Karabakhtsian RG, Johnson R, Sumkin J, Dabbs DJ. The clinical significance of lobular neoplasia on breast core biopsy. Am J Surg Pathol 2007;31:717-723
88. Menon S, Porter GJ, Evans AJ, et al. The significance of lobular neoplasia on needle core biopsy of the breast. Virchows Arch 2008;452:473-479
89. Middleton LP, Grant S, Stephens T, Stelling CB, Sneige N, Sahin AA. Lobular carcinoma in situ diagnosed by core needle biopsy: When should it be excised? Mod Pathol 2003;16:120-129
90. Renshaw AA, Derhagopian RP, Martinez P, Gould EW. Lobular neoplasia in breast core needle biopsy specimens is associated with a low risk of ductal carcinoma in situ or invasive carcinoma on subsequent excision. Am J Clin Pathol 2006;126:310-313
91. Lakhani SR, Audretsch W, Cleton-Jensen AM, et al. The management of lobular carcinoma in situ (LCIS). Is LCIS the same as ductal carcinoma in situ (DCIS)?. Eur J Cancer 2006;42:2205-2211
92. Liebens F, Cardinael AS, Schillings AP, et al. Current management of lobular in situ neoplasia. Jbr-Btr 2008;91:166-170